We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration
News

Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration

Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration
News

Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Syndexa Pharmaceuticals Corporation and ChemDiv Announce Discovery Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

ChemDiv, Inc. and Syndexa Pharmaceuticals Corporation have announced the signing of a collaborative discovery research agreement. Under the terms of the agreement, ChemDiv will discover small molecule ligands for biotargets nominated by Syndexa. Financial terms of the collaboration were not disclosed.

"We are very excited to deploy our discovery resources in this collaboration with Syndexa," said Dr. Ilya Okun, VP of Biology & CTO at ChemDiv, Inc. "ChemDiv's flexible service capabilities emphasize delivery of rapid, high-value results for our partners' drug discovery programs. We are able to realize that goal through the creative integration of the chemistry and biology components of our Discovery outsource™ platform."

"We are extremely pleased to be working with ChemDiv, a drug discovery partner with a strong track record. The collaboration will provide us with access to high quality screening capabilities and compound library resources. We anticipate that this project will accomplish our goal of discovering promising drug leads to enhance our R&D pipeline," said Teo Uysal, President and CEO, Syndexa Pharmaceuticals.

Advertisement